SCHEMBL195829

SCHEMBL195829

COC(=O)C1C2CCC(C2)C1(C)C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35
ALDH1A1 P00352 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ATM Q13315 1/20 0.33
TP53 P04637 1/20 0.33
HDAC6 Q9UBN7 2/20 0.32
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32
SLC6A3 Q01959 1/20 0.32
CYP3A4 P08684 3/20 0.31
MAPT P10636 2/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6551752 0.79 ALDH1A1 (0.33) ALDH1A1NPSR1
SCHEMBL453690 0.79 NPSR1 (0.33) ALDH1A1NPSR1MEN1CYP1A2CYP2C9
SCHEMBL10785435 0.77 ALDH1A1 (0.38) ALDH1A1NPSR1
SCHEMBL10783764 0.76 CYP19A1 (0.44)
SCHEMBL8996537 0.76 MAPT (0.48) ALDH1A1CYP2C19KMT2AMAPT
SCHEMBL11216927 0.74
SCHEMBL4822714 0.72 POLB (0.52) ALDH1A1MAPT
SCHEMBL10937315 0.71 ALDH1A1 (0.33) ALDH1A1NPSR1
SCHEMBL10937317 0.71 ALDH1A1 (0.33) ALDH1A1NPSR1
SCHEMBL11532435 0.71 ALDH1A1 (0.33) ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018145219-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING SERANI MOSTAZAL JORGE (CL) 2018-08-16 WO claimed
US-20140227201-A1 Antimicrobial Gel Formulations NOVABAY PHARMACEUTICALS, INC. 2014-08-14 US claimed
JP-2012500209-A 2012-01-05 JP claimed
EP-2312939-A1 ANTIMICROBIAL GEL FORMULATIONS NovaBay Pharmaceuticals, Inc. (US) 2011-04-27 EP claimed
US-20100076089-A1 ANTIMICROBIAL GEL FORMULATIONS NOVABAY PHARMACEUTICALS, INC. 2010-03-25 US claimed
WO-2010019723-A1 ANTIMICROBIAL GEL FORMULATIONS NOVABAY PHARMACEUTICALS, INC. (US) 2010-02-18 WO claimed
US-6727221-B1 APPLYING TO HUMAN SKIN A PERFUME COMPOSITION COMPRISING AT LEAST 50% BY WEIGHT OF PERFUME COMPONENTS HAVING A MINIMUM INHIBITORY CONCENTRATION (MIC) FOR CORYNEFORM BACTERIA OF GREATER THAN 0.1% QUEST INTERNATIONAL B.V. (NL) 2004-04-27 US claimed
EP-1094784-B1 PERFUME COMPOSITION QUEST INT (NL) 2004-02-11 EP claimed
EP-1094784-A1 PERFUME COMPOSITION QUEST INTERNATIONAL B.V. (NL) 2001-05-02 EP claimed
WO-2000001352-A1 PERFUME COMPOSITION QUEST INTERNATIONAL B.V. (NL) 2000-01-13 WO claimed
WO-1993021295-A1 LIQUID OR GEL BLEACHING COMPOSITION CONTAINING AMIDOPEROXYACID BLEACH AND PERFUME THE PROCTER & GAMBLE COMPANY (US) 1993-10-28 WO claimed
WO-1993021296-A1 AQUEOUS LIQUID BLEACH COMPOSITIONS WITH FLUORESCENT WHITENING AGENT AND POLYVINYL PYRROLIDONE OR POLYVINYL ALCOHOL THE PROCTER & GAMBLE COMPANY (US) 1993-10-28 WO claimed
US-5248434-A Stability THE PROCTOR & GAMBLE COMPANY (US) 1993-09-28 US claimed
US-5234617-A Cleaning, bleaching fabrics Hunter, Kathleen B. (US) 1993-08-10 US claimed
US-12461089-B2 Olfactory receptor involved in the perception of musk fragrance and the use thereof CHEMOSENSORYX BIOSCIENCES SA (BE) 2025-11-04 US disclosed
US-20240319168-A1 OLFACTORY RECEPTOR INVOLVED IN THE PERCEPTION OF MUSK FRAGRANCE AND THE USE THEREOF CHEMOSENSORYX BIOSCIENCES SA (BE) 2024-09-26 US disclosed
US-20240041752-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2024-02-08 US disclosed
US-5248434-A Stability THE PROCTOR & GAMBLE COMPANY (US) 1993-09-28 US disclosed
US-5234617-A Cleaning, bleaching fabrics Hunter, Kathleen B. (US) 1993-08-10 US disclosed
US-4442025-A Perfume compositions and perfumed articles containing esters of substituted bicyclo [2.2.1]heptane and heptene-carboxylic acids as perfume base NAARDEN INTERNATIONAL, N.V. (NL) 1984-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140227201-A1 Antimicrobial Gel Formulations CUTA, TUBA3C, POLR1C CHRNB2 4829/4885CHRNB4 4839/4885CHRNA3 4713/4885
US-20240041752-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AOX1, TYR, OCIAD1 CHRNB2 3601/4885CHRNB4 3932/4885CHRNA3 4535/4885
US-20100076089-A1 ANTIMICROBIAL GEL FORMULATIONS CUTA, TUBA3C, POLR1C CHRNB2 4829/4885CHRNB4 4839/4885CHRNA3 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.